Role of microRNAs in response to cadmium chloride in pancreatic ductal adenocarcinoma.


Journal

Archives of toxicology
ISSN: 1432-0738
Titre abrégé: Arch Toxicol
Pays: Germany
ID NLM: 0417615

Informations de publication

Date de publication:
02 2022
Historique:
received: 07 09 2021
accepted: 10 11 2021
pubmed: 15 12 2021
medline: 29 3 2022
entrez: 14 12 2021
Statut: ppublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal and aggressive malignancies with a 5-year survival rate less than 9%. Early detection is particularly difficult due to the lack of symptoms even in advanced stages. microRNAs (miRs/miRNAs) are small (~ 18-24 nucleotides), endogenous, non-coding RNAs, which are involved in the pathogenesis of several malignancies including PDAC. Alterations of miR expressions can lead to apoptosis, angiogenesis, and metastasis. The role of environmental pollutants such as cadmium (Cd) in PDAC has been suggested but not fully understood. This study underlines the role of miRs (miR-221, miR-155, miR-126) in response to cadmium chloride (CdCl

Identifiants

pubmed: 34905088
doi: 10.1007/s00204-021-03196-9
pii: 10.1007/s00204-021-03196-9
pmc: PMC8837568
doi:

Substances chimiques

Environmental Pollutants 0
MIRN126 microRNA, human 0
MIRN155 microRNA, human 0
MIRN221 microRNA, human 0
MicroRNAs 0
Cadmium Chloride J6K4F9V3BA

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

467-485

Informations de copyright

© 2021. The Author(s).

Références

Abbruzzese JL (2008) Adjuvant therapy for surgically resected pancreatic adenocarcinoma. JAMA 299(9):1066–1067. https://doi.org/10.1001/jama.299.9.1066
doi: 10.1001/jama.299.9.1066 pubmed: 18319419
Ahn YH, Gibbons DL, Chakravarti D, Creighton CJ, Rizvi ZH, Adams HP, Pertsemlidis A, Gregory PA, Wright JA, Goodall GJ et al (2012) ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Investig 122(9):3170–3183. https://doi.org/10.1172/JCI63608
doi: 10.1172/JCI63608 pubmed: 22850877 pmcid: 3428095
Alemar B, Izetti P, Gregório C, Macedo GS, Castro MAA, Osvaldt AB, Matte U, Ashton-Prolla P (2016) miRNA-21 and miRNA-34a are potential minimally invasive biomarkers for the diagnosis of pancreatic ductal adenocarcinoma. Pancreas 45(1):84–92. https://doi.org/10.1097/MPA.0000000000000383
doi: 10.1097/MPA.0000000000000383 pubmed: 26262588
Ali S, Dubaybo H, Brand RE, Sarkar FH (2015) Differential expression of microRNAs in tissues and plasma co-exists as a biomarker for pancreatic cancer. J Cancer Sci Ther 7(11):336–346. https://doi.org/10.4172/1948-5956.1000372
doi: 10.4172/1948-5956.1000372 pubmed: 26819679 pmcid: 4725594
Amirkhah R, Schmitz U, Linnebacher M, Wolkenhauer O, Farazmand A (2015) MicroRNA-mRNA interactions in colorectal cancer and their role in tumour progression. Genes Chromosomes Cancer 54(3):129–141. https://doi.org/10.1002/gcc.22231
doi: 10.1002/gcc.22231 pubmed: 25620079
Anđelković M, Djordjevic AB, Miljaković EA, Javorac D, Čolaković N, Oprić S, Petričević S, Granić M, Kotur-Stevuljević J, Antonijević B, Bulat Z (2021) Cadmium tissue level in women diagnosed with breast cancer—A case control study. Environ Res 199:111300. https://doi.org/10.1016/j.envres.2021.111300
doi: 10.1016/j.envres.2021.111300 pubmed: 34015299
Arisan ED, Rencuzogullari O, Freitas IL, Radzali S, Keskin B, Kothari A, Warford A, Uysal-Onganer P (2020) Upregulated Wnt-11 and miR-21 expression trigger epithelial mesenchymal transition in aggressive prostate cancer cells. Biology 9(3):52. https://doi.org/10.3390/biology9030052
doi: 10.3390/biology9030052 pmcid: 7150874
Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL et al (2009) Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69:5820–5828. https://doi.org/10.1158/0008-5472.CAN-08-2819
doi: 10.1158/0008-5472.CAN-08-2819 pubmed: 19584296 pmcid: 4378690
Babar IA, Czochor J, Steinmetz A, Weidhaas JB et al (2011) Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biol Ther 12(10):908–914. https://doi.org/10.4161/cbt.12.10.17681
doi: 10.4161/cbt.12.10.17681 pubmed: 22027557 pmcid: 3280906
Bakirtzi K, Hatziapostolou M, Karagiannides I et al (2011) Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumour growth in mice, and is increased in human colon tumours. Gastroenterology 141(5):1749–1761. https://doi.org/10.1053/j.gastro.2011.07.038
doi: 10.1053/j.gastro.2011.07.038 pubmed: 21806946
Ballehaninna UK, Chamberlain RS (2013) Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19–9. Tumour Biol 34(6):3279–3292. https://doi.org/10.1007/s13277-013-1033-3
doi: 10.1007/s13277-013-1033-3 pubmed: 23949878
Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297. https://doi.org/10.1016/S0092-8674(04)00045-5
doi: 10.1016/S0092-8674(04)00045-5 pubmed: 14744438 pmcid: 14744438
Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM (2007) MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297(17):1901–1908. https://doi.org/10.1001/jama.297.17.1901
doi: 10.1001/jama.297.17.1901 pubmed: 17473300
Bortesi L, Pesci A, Bogina G, Castelli P, Zamboni G (2011) Ductal adenocarcinoma of the pancreas. Surg Pathol Clin. 4(2):487–521. https://doi.org/10.1016/j.path.2011.03.007
doi: 10.1016/j.path.2011.03.007 pubmed: 26837485
Brabletz S, Bajdak K, Meidhof S, Burk U, Niedermann G, Firat E, Wellner U, Dimmler A, Faller G, Schubert J et al (2011) The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J 30(4):770–782. https://doi.org/10.1038/emboj.2010.349
doi: 10.1038/emboj.2010.349 pubmed: 21224848 pmcid: 3041948
Brabletz T, Kalluri R, Nieto MA, Weinberg RA (2018) EMT in cancer. Nat Rev Cancer 18(2):128–134. https://doi.org/10.1038/nrc.2017.118
doi: 10.1038/nrc.2017.118 pubmed: 29326430
Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D et al (2007) Loss of homotypic cell adhesion by epithelial–mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 6(2):532–541. https://doi.org/10.1158/1535-7163.MCT-06-0462
doi: 10.1158/1535-7163.MCT-06-0462 pubmed: 17308052
Buha A, Wallace D, Matovic V et al (2017) Cadmium exposure as a putative risk factor for the development of pancreatic cancer: three different lines of evidence. Biomed Res Int 2017:1981837. https://doi.org/10.1155/2017/1981837
doi: 10.1155/2017/1981837 pubmed: 29349066 pmcid: 5733953
Buha A, Matovic V, Antonijevic B, Bulat Z, Curcic M, Renieri EA, Tsatsakis AM, Schweitzer A, Wallace D (2018) Overview of cadmium thyroid disrupting effects and mechanisms. Int J Mol Sci 19(5):1501. https://doi.org/10.3390/ijms19051501
doi: 10.3390/ijms19051501 pmcid: 5983752
Buha A, Jugdaohsingh R, Matovic V, Bulat Z, Antonijevic B, Kerns JG, Goodship A, Hart A, Powell JJ (2019) Bone mineral health is sensitively related to environmental cadmium exposure–experimental and human data. Environ Res 176:108539. https://doi.org/10.1016/j.envres.2019.108539
doi: 10.1016/j.envres.2019.108539 pubmed: 31247431
Buha A, Đukić-Ćosić D, Ćurčić M, Bulat Z, Antonijević B, Moulis JM, Goumenou M, Wallace D (2020) Emerging links between cadmium exposure and insulin resistance: human, animal, and cell study data. Toxics 8(3):63. https://doi.org/10.3390/toxics8030063
doi: 10.3390/toxics8030063 pmcid: 7560347
Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T (2008) A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9:582–589
doi: 10.1038/embor.2008.74
Calatayud D, Dehlendorff C, Boisen MK, Hasselby JP, Schultz NA, Werner J, Immervoll H, Molven A, Hansen CP, Johansen JS (2017) Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers. Biomark Res 5:e8. https://doi.org/10.1186/s40364-017-0087-6
doi: 10.1186/s40364-017-0087-6
Chakraborty C, George Priya Doss C, Bandyopadhyay S (2013) miRNAs in insulin resistance and diabetes-associated pancreatic cancer: the “minute and miracle” molecule moving as a monitor in the “genomic galaxy.” Curr Drug Targets United Arab Emirates 14(10):1110–1117. https://doi.org/10.2174/13894501113149990182
doi: 10.2174/13894501113149990182
Chan A et al (2014) Validation of biomarkers that complement ca19.9 in detecting early pancreatic cancer. Clin Cancer Res 20:5787–5795
doi: 10.1158/1078-0432.CCR-14-0289
Chang JC, Kundranda M (2017) Novel diagnostic and predictive biomarkers in pancreatic adenocarcinoma. Int J Mol Sci 18(3):e667. https://doi.org/10.3390/ijms18030667
doi: 10.3390/ijms18030667 pubmed: 28335509
Chen L, Xu B, Liu L, Luo Y, Zhou H, Chen W et al (2011) Cadmium induction of reactive oxygen species activates the mTOR pathway, leading to neuronal cell death. Free Radic Biol Med 50:624–632. https://doi.org/10.1016/j.freeradbiomed.2010.12.032
doi: 10.1016/j.freeradbiomed.2010.12.032 pubmed: 21195169
Chen Z, Pan T, Jiang D, Jin L, Geng Y, Feng X et al (2020) The lncRNA-GAS5/miR-221-3p/DKK2 axis modulates ABCB1-mediated adriamycin resistance of breast cancer via the Wnt/β-catenin signaling pathway. Mol Ther 19:1434–1448. https://doi.org/10.1016/j.omtn.2020.01.030
doi: 10.1016/j.omtn.2020.01.030
Dart DA, Arisan DE, Owen S, Hao C, Jiang WG, Uysal-Onganer P (2019) Wnt-11 expression promotes invasiveness and correlates with survival in human pancreatic ductal adenocarcinoma. Genes 10(11):921. https://doi.org/10.3390/genes10110921
doi: 10.3390/genes10110921 pmcid: 6895970
De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13(2):97–110. https://doi.org/10.1038/nrc3447
doi: 10.1038/nrc3447 pubmed: 23344542
Dhayat SA, Abdeen B, Köhler G, Senninger N, Haier J, Mardin WA (2015) MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II. Clin Epigenet 7:e132. https://doi.org/10.1186/s13148-015-0166-1
doi: 10.1186/s13148-015-0166-1
Djordjevic VR, Wallace DR, Schweitzer A, Boricic N, Knezevic D, Matic S, Grubor N, Kerkez M, Radenkovic D, Bulat Z et al (2019) Environmental cadmium exposure and pancreatic cancer: evidence from case control, animal and in vitro studies. Environ Int 128:353–361. https://doi.org/10.1016/j.envint.2019.04.048
doi: 10.1016/j.envint.2019.04.048 pubmed: 31078004
Fathi M, Ghafouri-Fard S, Abak A, Taheri M (2021) Emerging roles of miRNAs in the development of pancreatic cancer. Biomed Pharmacother 141:111914. https://doi.org/10.1016/j.biopha.2021.111914
doi: 10.1016/j.biopha.2021.111914 pubmed: 34328099
Fedele M, Cerchia L, Chiappetta G (2017) The epithelial-to-mesenchymal transition in breast cancer: focus on basal-like carcinomas. Cancers 9(10):134. https://doi.org/10.3390/cancers9100134
doi: 10.3390/cancers9100134 pmcid: 5664073
Felipe Lima J, Nofech-Mozes S, Bayani J, Bartlett JMS (2016) EMT in breast carcinoma—a review. J Clin Med 5(7):65. https://doi.org/10.3390/jcm5070065
doi: 10.3390/jcm5070065 pmcid: 4961996
Feng R et al (2010) miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett 298:50–63
doi: 10.1016/j.canlet.2010.06.004
Feng H, Wang Y, Su J, Liang H, Zhang CY, Chen X, Yao W (2016) MicroRNA-148a suppresses the proliferation and migration of pancreatic cancer cells by down-regulating ErbB3. Pancreas 45(9):1263–1271. https://doi.org/10.1097/MPA.0000000000000677
doi: 10.1097/MPA.0000000000000677 pubmed: 27776045
Garajová I, le Large TY, Frampton AE, Rolfo C, Voortman J, Giovannetti E (2014) Molecular mechanisms underlying the role of MicroRNAs in the chemoresistance of pancreatic cancer. BioMed Res Int 2014:1–17. https://doi.org/10.1155/2014/678401
doi: 10.1155/2014/678401
Garofalo M, Quintavalle C, Di LG, Zanca C, Romano G, Taccioli C, Liu CG, Croce CM, Condorelli G (2008) MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 27(27):3845–3855. https://doi.org/10.1038/onc.2008.6
doi: 10.1038/onc.2008.6 pubmed: 18246122
Gayral M, Jo S, Hanoun N, Vignolle-Vidoni A, Lulka H, Delpu Y, Meulle A, Dufresne M, Humeau M, Chalret du Rieu M et al (2014) MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. World J Gastroenterol 20(32):11199–11209. https://doi.org/10.3748/wjg.v20.i32.11199
doi: 10.3748/wjg.v20.i32.11199 pubmed: 25170204 pmcid: 4145758
Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L, Negrini M (2009) MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumour multifocality. Clin Cancer Res 15(16):5073–5081. https://doi.org/10.1158/1078-0432.CCR-09-0092
doi: 10.1158/1078-0432.CCR-09-0092 pubmed: 19671867 pmcid: 3900721
Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10(5):593–601. https://doi.org/10.1038/ncb1722
doi: 10.1038/ncb1722 pubmed: 18376396 pmcid: 18376396
Greither T et al (2010) Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumours is associated with poorer survival. Int J Cancer 126(1):73–80. https://doi.org/10.1002/ijc.24687
doi: 10.1002/ijc.24687 pubmed: 19551852
Grutzmann R (2004) ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 90(5):1053–1058. https://doi.org/10.1038/sj.bjc.6601645
doi: 10.1038/sj.bjc.6601645 pubmed: 14997207 pmcid: 2409625
Guo X, Wang XF (2009) Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res 19(1):71–88. https://doi.org/10.1038/cr.2008.302
doi: 10.1038/cr.2008.302 pubmed: 19002158
Hamada S, Satoh K, Miura S, Hirota M, Kanno A, Masamune A, Kikuta K, Kume K, Unno J, Egawa S et al (2013) miR-197 induces epithelial–mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physiol 228(6):1255–1263. https://doi.org/10.1002/jcp.24280
doi: 10.1002/jcp.24280 pubmed: 23139153
Harazono Y, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, Inazawa J, Kozaki K (2013) miR-655 Is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. PLoS ONE 8(5):e62757. https://doi.org/10.1371/journal.pone.0062757
doi: 10.1371/journal.pone.0062757 pubmed: 23690952 pmcid: 3653886
Hidalgo M et al (2015) Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology 15(1):8–18. https://doi.org/10.1016/j.pan.2014.10.001
doi: 10.1016/j.pan.2014.10.001 pubmed: 25547205
Hong SM, Li A, Olino K, Wolfgang CL, Herman JM, Schulick RD, Iacobuzio-Donahue C, Hruban RH, Goggins M (2011) Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinoma. Mod Pathol 24:1237–1247. https://doi.org/10.1038/modpathol.2011.74
doi: 10.1038/modpathol.2011.74 pubmed: 21552209 pmcid: 3155013
Hotz B, Arndt M, Dullat S, Bhargava S, Buhr HJ, Hotz HG (2007) Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res 13:4769–4776. https://doi.org/10.1158/1078-0432.CCR-06-2926
doi: 10.1158/1078-0432.CCR-06-2926 pubmed: 17699854
Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED (2007) Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213(2):374–383. https://doi.org/10.1002/jcp.21223
doi: 10.1002/jcp.21223 pubmed: 17680632
Humphries B, Yang C (2015) The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget 6(9):6472–6498. https://doi.org/10.18632/oncotarget.3052
doi: 10.18632/oncotarget.3052 pubmed: 25762624 pmcid: 4466628
Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P et al (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27(11):1806–1813. https://doi.org/10.1200/JCO.2008.17.7188
doi: 10.1200/JCO.2008.17.7188 pubmed: 2668706 pmcid: 2668706
Jiang N, Jiang X, Chen Z, Song X, Wu L, Zong D, Song D, Yin L, Wang D, Chen C et al (2017) MiR-203a-3p suppresses cell proliferation and metastasis through inhibiting LASP1 in nasopharyngeal carcinoma. J Exp Clin Cancer Res 36(1):e138. https://doi.org/10.1186/s13046-017-0604-3
doi: 10.1186/s13046-017-0604-3
Jiao LR, Frampton AE, Jacob J, Pellegrino L, Krell J, Giamas G, Tsim N, Vlavianos P, Cohen P, Ahmad R et al (2012) MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transfor-mation from benign tumours. PLoS ONE 7:e32068. https://doi.org/10.1371/journal.pone.0032068
doi: 10.1371/journal.pone.0032068 pubmed: 22384141 pmcid: 3284550
Kalluri R, Weinberg RA (2009) The basics of epithelial mesenchymal transition. J Clin Invest 119(2009):1420–1428. https://doi.org/10.1172/JCI39104
doi: 10.1172/JCI39104 pubmed: 19487818 pmcid: 2689101
Khakinezhad Tehrani F, Ranji N, Kouhkan F, Hosseinzadeh S (2021) PANC-1 cancer stem-like cell death with silybin encapsulated in polymersomes and deregulation of stemness-related miRNAs and their potential targets. Iranian J Basic Med Sci 24(4):514–523. https://doi.org/10.22038/ijbms.2021.54001.12136
doi: 10.22038/ijbms.2021.54001.12136
Komoto M, Nakata B, Amano R, Yamada N, Yashiro M, Ohira M, Wakasa K, Hirakawa K (2009) HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci 100(7):1243–1247. https://doi.org/10.1111/j.1349-7006.2009.01176.x
doi: 10.1111/j.1349-7006.2009.01176.x pubmed: 19432892
Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P et al (2017) The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol 19(5):518–529. https://doi.org/10.1038/ncb3513
doi: 10.1038/ncb3513 pubmed: 28414315
Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol 15(3):178–196. https://doi.org/10.1038/nrm3758
doi: 10.1038/nrm3758 pubmed: 24556840 pmcid: 4240281
Lee TK, Poon RTP, Yuen AP, Ling MT, Kwok WK, Wang XH (2006) Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial–mesenchymal transition. Clin Cancer Res 12(18):5369–5376. https://doi.org/10.1158/1078-0432.ccr-05-2722
doi: 10.1158/1078-0432.ccr-05-2722 pubmed: 17000670
Li QQ, Xu JD, Wang WJ et al (2009) Twist1-mediated adriamycin-induced epithelial–mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 15(8):2657–2665. https://doi.org/10.1158/1078-0432.CCR-08-2372
doi: 10.1158/1078-0432.CCR-08-2372 pubmed: 19336515
Li A, Omura N, Hong SM, Vincent A, Walter K, Griffith M, Borges M, Goggins M (2010) Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 70(13):5226–5237. https://doi.org/10.1158/0008-5472.CAN-09-4227
doi: 10.1158/0008-5472.CAN-09-4227 pubmed: 20551052 pmcid: 3130565
Lima RT, Busacca S, Almeida GM, Gaudino G, Fennell DA, Vasconcelos MH (2011) MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer 47(2):163–174. https://doi.org/10.1016/j.ejca.2010.11.005
doi: 10.1016/j.ejca.2010.11.005 pubmed: 21145728
Lin S, Gregory RI (2015) MicroRNA biogenesis pathways in cancer. Nat Rev Cancer 15:321–333. https://doi.org/10.1038/nrc3932
doi: 10.1038/nrc3932 pubmed: 25998712 pmcid: 25998712
Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B (2010) The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF- B/Snail/RKIP/PTEN Circuit. Genes Cancer 1(5):409–420. https://doi.org/10.1177/1947601910373795
doi: 10.1177/1947601910373795 pubmed: 20827424 pmcid: 2933925
Liu J, Qu W, Kadiiska MB (2009) Role of oxidative stress in cadmium toxicity and carcinogenesis. Toxicol Appl Pharmacol 238:209–214. https://doi.org/10.1016/j.taap.2009.01.029
doi: 10.1016/j.taap.2009.01.029 pubmed: 19236887 pmcid: 4287357
Liu M, Liu J, Wang L, Wu H, Zhou C, Zhu H, Xu N, Xie Y (2014) Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. PLoS ONE 9(10):e109347. https://doi.org/10.1371/journal.pone.0109347
doi: 10.1371/journal.pone.0109347 pubmed: 25275448 pmcid: 4183700
Liu Q, Zheng C, Shen H, Zhou Z, Lei Y (2015) MicroRNAs-mRNAs expression profile and their potential role in malignant transformation of human bronchial epithelial cells induced by cadmium. BioMed Res Int 2015:902025. https://doi.org/10.1155/2015/902025
doi: 10.1155/2015/902025 pubmed: 26504844 pmcid: 4609416
Lu X, Zhao P, Zhang C, Fu Z, Chen Y, Lu A, Liu N, You Y, Pu P, Kang C (2009) Analysis of miR-221 and p27 expression in human gliomas. Mol Med Rep 2(4):651–656. https://doi.org/10.3892/mmr_00000152
doi: 10.3892/mmr_00000152 pubmed: 21475881
Lu Y, Ji N, Wei W, Sun W, Gong X, Wang X (2017) MiR-142 modulates human pancreatic cancer proliferation and invasion by targeting hypoxia-inducible factor 1 (HIF-1α) in the tumour microenvironments. Biol Open 6(2):252–259
pubmed: 28069592 pmcid: 5312097
Maier HJ, Schmidt-Strassburger U, Huber MA, Wiedemann EM, Beug H, Wirth T (2010) NF-kappaB promotes epithelial–mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett 295(2):214–228. https://doi.org/10.1016/j.canlet.2010.03.003
doi: 10.1016/j.canlet.2010.03.003 pubmed: 20350779
Martinez-Zamudio R, Ha HC (2011) Environmental epigenetics in metal exposure. Epigenetics 6(7):820–827. https://doi.org/10.4161/epi.6.7.16250
doi: 10.4161/epi.6.7.16250 pubmed: 21610324 pmcid: 3230540
Masamune A, Nakano E, Hamada S, Takikawa T, Yoshida N, Shimosegawa T (2013) Alteration of the microRNA expression profile during the activation of pancreatic stellate cells. Scand J Gastroenterol 49(3):323–331. https://doi.org/10.3109/00365521.2013.876447
doi: 10.3109/00365521.2013.876447
McCubrey JA, Fitzgerald TL, Yang LV, Lertpiriyapong K, Steelman LS, Abrams SL, Montalto G, Cervello M, Neri LM, Cocco L et al (2016) Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget 8(8):14221–14250. https://doi.org/10.18632/oncotarget.13991
doi: 10.18632/oncotarget.13991 pmcid: 5355173
Meltzer PS (2005) Cancer genomics: small RNAs with big impacts. Nature 435:745–746. https://doi.org/10.1038/435745a
doi: 10.1038/435745a pubmed: 15944682
Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria R, Spagnoli LG, Farace MG, Ciafre SA (2008) The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE 3(12):e4029. https://doi.org/10.1371/journal.pone.0004029
doi: 10.1371/journal.pone.0004029 pubmed: 19107213 pmcid: 2603596
Mongroo PS, Rustgi AK (2010) The role of the miR-200 family in epithelial–mesenchymal transition. Cancer Biol Ther 10(3):219–222. https://doi.org/10.4161/cbt.10.3.12548
doi: 10.4161/cbt.10.3.12548 pubmed: 20592490 pmcid: 3040834
Mortoglou M, Wallace D, Buha Djordjevic A, Djordjevic V, Arisan ED, Uysal-Onganer P (2021a) MicroRNA-regulated signaling pathways: potential biomarkers for pancreatic ductal adenocarcinoma. Stresses 1(1):30–47. https://doi.org/10.3390/stresses1010004
doi: 10.3390/stresses1010004
Mortoglou M, Tabina ZK, Arisan ED, Kocher HM, Uysal-Onganer P (2021b) Non-coding RNAs in pancreatic ductal adenocarcinoma: new approaches for better diagnosis and therapy. Translational Oncology 14(7):101090. https://doi.org/10.1016/j.tranon.2021.101090
doi: 10.1016/j.tranon.2021.101090 pubmed: 33831655 pmcid: 8042452
Mou T, Zhu D, Wei X, Li T, Zheng D, Pu J et al (2017) Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis. World J Surg Oncol 15(1):1–9. https://doi.org/10.1186/s12957-017-1127-2
doi: 10.1186/s12957-017-1127-2
Murillo-Garzón V, Gorroño-Etxebarria I, Åkerfelt M, Puustinen MC, Sistonen L, Nees M, Carton J, Waxman J, Kypta RM (2018) Frizzled-8 integrates Wnt-11 and transforming growth factor-β signaling in prostate cancer. Nat Commun 9(1):1747. https://doi.org/10.1038/s41467-018-04042-w
doi: 10.1038/s41467-018-04042-w pubmed: 29717114 pmcid: 5931552
Nakamura M, Tokura Y (2011) Epithelial-mesenchymal transition in the skin. J Dermatol Sci 61(1):7–13. https://doi.org/10.1016/j.jdermsci.2010.11.015
doi: 10.1016/j.jdermsci.2010.11.015 pubmed: 21167690
Ngalame NNO, Waalkes MP, Tokar EJ (2016) Silencing KRAS Overexpression in Cadmium-Transformed Prostate Epithelial Cells Mitigates Malignant Phenotype. Chem Res Toxicol 29:1458–1467
doi: 10.1021/acs.chemrestox.6b00137
Nikiforova MN, Tseng GC, Steward D et al (2008) MicroRNA expression profiling of thyroid tumours: biological significance and diagnostic utility. J Clin Endocrinol Metab 93(5):1600–1608. https://doi.org/10.1210/jc.2007-2696
doi: 10.1210/jc.2007-2696 pubmed: 18270258 pmcid: 2386678
Otsuka K, Ochiya T (2014) Genetic networks lead and follow tumour development: microRNA regulation of cell cycle and apoptosis in the p53 pathways. Biomed Res Int. https://doi.org/10.1155/2014/749724
doi: 10.1155/2014/749724 pubmed: 25302307 pmcid: 4180389
Ouyang H, Gore J, Deitz S, Korc M (2014) microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions. Oncogene 33(38):4664–4674. https://doi.org/10.1038/onc.2013.405
doi: 10.1038/onc.2013.405 pubmed: 24096486
Papaconstantinou IG et al (2013) Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas 42(1):67–71. https://doi.org/10.1097/MPA.0b013e3182592ba7
doi: 10.1097/MPA.0b013e3182592ba7 pubmed: 22850622
Park J-K, Lee EJ, Esau C, Schmittgen TD (2009) Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 38(7):e190–e199. https://doi.org/10.1097/MPA.0b013e3181ba82e1
doi: 10.1097/MPA.0b013e3181ba82e1 pubmed: 19730150
Pellegrini KL, Gerlach CV, Craciun FL, Ramachandran K, Bijol V, Kissick HT, Vaidya VS (2016) Application of small RNA sequencing to identify microRNAs in acute kidney injury and fibrosis. Toxicol Appl Pharmacol 312:42–52
doi: 10.1016/j.taap.2015.12.002
Peng L, Liu Z, Xiao J, Tu Y, Wan Z, Xiong H, Li Y, Xiao W (2017) MicroRNA-148a suppresses epithelial–mesenchymal transition and invasion of pancreatic cancer cells by targeting Wnt10b and inhibiting the Wnt/β-catenin signaling pathway. Oncol Rep 38(1):301–308. https://doi.org/10.3892/or.2017.5705
doi: 10.3892/or.2017.5705 pubmed: 28586066
Peter ME (2009) Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 8:843–852
doi: 10.4161/cc.8.6.7907
Piasecka D, Braun M, Kordek R, Sadej R, Romanska H (2018) MicroRNAs in regulation of triple-negative breast cancer progression. J Cancer Res Clin Oncol 144(8):1401–1411. https://doi.org/10.1007/s00432-018-2689-2
doi: 10.1007/s00432-018-2689-2 pubmed: 29923083 pmcid: 6061037
Ribatti D, Tamma R, Annese T (2020) Epithelial-mesenchymal transition in cancer: a historical overview. Translational Oncology 13(6):100773. https://doi.org/10.1016/j.tranon.2020.100773
doi: 10.1016/j.tranon.2020.100773 pubmed: 32334405 pmcid: 7182759
Roche J (2018) The epithelial-to-mesenchymal transition in cancer. Cancers 10(2):52. https://doi.org/10.3390/cancers10020052
doi: 10.3390/cancers10020052 pmcid: 5836084
Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371(22):2140–2141. https://doi.org/10.1056/NEJMc1412266
doi: 10.1056/NEJMc1412266 pubmed: 25427123
Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A (2010) Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 10(1):66–73. https://doi.org/10.1159/000231984
doi: 10.1159/000231984 pubmed: 20332664 pmcid: 2865485
Sarkar S, Dubaybo H, Ali S, Goncalves P, Kollepara SL, Sethi S et al (2013) Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer Res 3(5):465–477
pubmed: 24224124 pmcid: 3816966
Scara S, Bottoni P, Scatena R (2015) Ca 19–9: Biochemical and clinical aspects. Adv Exp Med Biol 867:247–260
doi: 10.1007/978-94-017-7215-0_15
Sempere LF et al (2010) Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumours. Clin Cancer Res 16:4246–4255
doi: 10.1158/1078-0432.CCR-10-1152
Sethi S, Sethi S, Bluth MH (2018) Clinical implication of microRNAs in molecular pathology: an update for 2018. Clin Lab Med 38(2):237–251. https://doi.org/10.1016/j.cll.2018.02.003
doi: 10.1016/j.cll.2018.02.003 pubmed: 29776629
Seton-Rogers S (2016) Epithelial-mesenchymal transition: untangling EMT’s functions. Nat Rev Cancer 16(1):1. https://doi.org/10.1038/nrc.2015.6
doi: 10.1038/nrc.2015.6 pubmed: 26612535
Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics. CA Cancer J Clin 64(1):9–29. https://doi.org/10.3322/caac.21208
doi: 10.3322/caac.21208
Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29(34):4741–4751. https://doi.org/10.1038/onc.2010.215
doi: 10.1038/onc.2010.215 pubmed: 20531305 pmcid: 3176718
Słotwiński R, Lech G, Słotwińska SM (2018) MicroRNAs in pancreatic cancer diagnosis and therapy. CEJOI 43:314–324. https://doi.org/10.5114/ceji.2018.80051
doi: 10.5114/ceji.2018.80051
Song Q, An Q, Niu B, Lu X, Zhang N, Cao X (2019) Role of miR-221/222 in tumour development and the underlying mechanism. J Oncol. https://doi.org/10.1155/2019/7252013
doi: 10.1155/2019/7252013 pubmed: 31929798 pmcid: 6942871
Stemmler MP, Eccles RL, Brabletz S, Brabletz T (2019) Non-redundant functions of EMT transcription factors. Nat Cell Biol 21(1):102–112. https://doi.org/10.1038/s41556-018-0196-y
doi: 10.1038/s41556-018-0196-y pubmed: 30602760
Su A, He S, Tian B, Hu W, Zhang Z (2013) MicroRNA-221 mediates the effects of PDGF-BB on migration, proliferation, and the epithelial–mesenchymal transition in pancreatic cancer cells. PLoS ONE 8:e71309. https://doi.org/10.1371/journal.pone.0071309
doi: 10.1371/journal.pone.0071309 pubmed: 23967190 pmcid: 3742757
Szafranska AE, Davison TS, John J et al (2007) MicroRNA expression alterations are linked to tumourigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26(30):4442–4452. https://doi.org/10.1038/sj.onc.1210228
doi: 10.1038/sj.onc.1210228 pubmed: 17237814
Tan X, Banerjee P, Guo HF, Ireland S, Pankova D, Ahn Y, Nikolaidis IM, Liu X, Zhao Y, Xue Y et al (2017) Epithelial-to-mesenchymal transition drives a pro-metastatic Golgi compaction process through scaffolding protein PAQR11. J Clin Investig 127(1):117–131. https://doi.org/10.1172/JCI88736
doi: 10.1172/JCI88736 pubmed: 27869652
Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J et al (2018) The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Investig 128(4):1267–1282. https://doi.org/10.1172/JCI97225
doi: 10.1172/JCI97225 pubmed: 29324442 pmcid: 5873879
Tang J, Li Y, Wang J, Wen Z, Lai M, Zhang H (2016) Molecular mechanisms of microRNAs in regulating epithelial–mesenchymal transitions in human cancers. Cancer Lett 371(2):301–313. https://doi.org/10.1016/j.canlet.2015.11.043
doi: 10.1016/j.canlet.2015.11.043 pubmed: 26683775
Tang Y, Cheng TY, YS, (2017) miR-34a inhibits pancreatic cancer progression through Snail1-mediated epithelial–mesenchymal transition and the Notch signaling pathway. Sci Rep 7:e38232. https://doi.org/10.1038/srep38232
doi: 10.1038/srep38232
Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H, Yu H (2014) Prognostic value of mir-221-3p, mir-342-3p and mir-491-5p expression in colon cancer. Am J Transl Res 6(4):391–401
pubmed: 25075256 pmcid: 4113501
Urani C, Melchioretto P, Fabbri M, Bowe G, Maserati E, Gribaldo L (2014) Cadmium impairs p53 activity in HepG2 cells. ISRN Toxicol 2014:976428
doi: 10.1155/2014/976428
Uysal-Onganer P, Kawano Y, Caro M et al (2010) Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer 9:55. https://doi.org/10.1186/1476-4598-9-55
doi: 10.1186/1476-4598-9-55 pubmed: 20219091 pmcid: 2846888
Uysal-Onganer P, D’Alessio S, Mortoglou M, Kraev I, Lange S (2021) Peptidylarginine deiminase inhibitor application, using Cl-Amidine, PAD2, PAD3 and PAD4 isozyme-specific inhibitors in pancreatic cancer cells, reveals roles for PAD2 and PAD3 in cancer invasion and modulation of extracellular vesicle signatures. Int J Mol Sci 22(3):1396. https://doi.org/10.3390/ijms22031396
doi: 10.3390/ijms22031396 pubmed: 33573274 pmcid: 7866560
Vega S, Morales AV, Ocaña OH, Valdés F, Fabregat I, Nieto MA (2004) Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 18(10):1131–1143. https://doi.org/10.1101/gad.294104
doi: 10.1101/gad.294104 pubmed: 15155580 pmcid: 415638
Von Hoff DD, Korn R, Mousses S (2009) Pancreatic cancer–could it be that simple? A different context of vulnerability. Cancer Cell 16(1):7–8. https://doi.org/10.1016/j.ccr.2009.06.011
doi: 10.1016/j.ccr.2009.06.011
Waisberg M, Joseph P, Hale B, Beyersmann D (2003) Molecular and cellular mechanisms of cadmium carcinogenesis. Toxicology 192:95–117. https://doi.org/10.1016/S0300-483X(03)00305-6
doi: 10.1016/S0300-483X(03)00305-6 pubmed: 14580780
Wallace DR, Spandidos DA, Tsatsakis A, Schweitzer A, Djordjevic V, Djordjevic AB (2019) Potential interaction of cadmium chloride with pancreatic mitochondria: implications for pancreatic cancer. Int J Mol Med 44(1):145–156. https://doi.org/10.3892/ijmm.2019.4204
doi: 10.3892/ijmm.2019.4204 pubmed: 31115542 pmcid: 6559323
Wallace DR, Taalab YM, Heinze S, Tariba Lovaković B, Pizent A, Renieri E, Tsatsakis A, Farooqi AA, Javorac D, Andjelkovic M, Bulat Z, Antonijević B, Buha Djordjevic A (2020) Toxic-metal-induced alteration in miRNA expression profile as a proposed mechanism for disease development. Cells 9(4):901. https://doi.org/10.3390/cells9040901
doi: 10.3390/cells9040901 pmcid: 7226740
Wang X, Liu D, Zhou K, Wang B, Liu Q, Deng F, Li Q, Ma Y (2016) Expression of Wnt-11 and Rock2 in esophageal squamous cell carcinoma by activation of the WNT/PCP pathway and its clinical significance. Pathol Res Pract 212(10):880–885. https://doi.org/10.1016/j.prp.2016.07.008
doi: 10.1016/j.prp.2016.07.008 pubmed: 27628667
Wang S, Huang S, Sun YL (2017) Epithelial-mesenchymal transition in pancreatic cancer: a review. Biomed Res Int 2017:2646148. https://doi.org/10.1155/2017/2646148
doi: 10.1155/2017/2646148 pubmed: 29379795 pmcid: 5742883
Wang L, Yao M, Fang M, Zheng WJ, Dong ZZ, Pan LH, Zhang HJ, Yao DF (2018a) Expression of hepatic Wnt5a and its clinicopathological features in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 17(3):227–232. https://doi.org/10.1016/j.hbpd.2018.03.005
doi: 10.1016/j.hbpd.2018.03.005 pubmed: 29709351
Wang W, Chen J, Luo L, Li Y, Liu J, Zhang W (2018b) Effect of cadmium on kitl pre-mRNA alternative splicing in murine ovarian granulosa cells and its associated regulation by miRNAs. J Appl Toxicol 38:227–239
doi: 10.1002/jat.3516
Wei H, Wang N, Zhang Y, Wang S, Pang X, Zhang J, Luo Q, Su Y, Zhang S (2014) Clinical significance of Wnt-11 and squamous cell carcinoma antigen expression in cervical cancer. Med Oncol 31(5):933. https://doi.org/10.1007/s12032-014-0933-4
doi: 10.1007/s12032-014-0933-4 pubmed: 24737009
Wei C, Xiang S, Yu Y, Song J, Zheng M, Lian F (2021) miR-221-3p regulates apoptosis of ovarian granulosa cells via targeting FOXO1 in older women with diminished ovarian reserve (DOR). Mol Reprod Dev 88(4):251–260. https://doi.org/10.1002/mrd.23457
doi: 10.1002/mrd.23457 pubmed: 8251591 pmcid: 8251591
Winter JM, Ting AH, Vilardell F, Gallmeier E, Baylin SB, Hruban RH, Kern SE, Iacobuzio-Donahue CA (2008) Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 14(2):412–418. https://doi.org/10.1158/1078-0432.CCR-07-0487
doi: 10.1158/1078-0432.CCR-07-0487 pubmed: 18223216
Winter JM, Yeo CJ, Brody JR (2013) Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol 107(1):15–22. https://doi.org/10.1002/jso.23192
doi: 10.1002/jso.23192 pubmed: 22729569
Xu Q et al (2015) miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Oncotarget 6(16):14153–14164
doi: 10.18632/oncotarget.3686
Yamakuchi M (2012) MicroRNA regulation of SIRT1. Front Physiol 3:1–8. https://doi.org/10.3389/fphys.2012.00068
doi: 10.3389/fphys.2012.00068
Yang W, Yang Y, Xia L, Yang Y, Wang F, Song M, Chen X, Liu J, Song Y, Zhao Y et al (2016) MiR-221 Promotes Capan-2 Pancreatic Ductal Adenocarcinoma Cells Proliferation by Targeting PTEN-Akt. Cell Physiol Biochem 38(6):2366–2374. https://doi.org/10.1159/000445589
doi: 10.1159/000445589 pubmed: 27230035
Yang H, Wang L, Tang X, Bai W (2017) miR-203a suppresses cell proliferation by targeting E2F transcription factor 3 in human gastric cancer. Oncol Lett 14(6):7687–7690. https://doi.org/10.3892/ol.2017.7199
doi: 10.3892/ol.2017.7199 pubmed: 29344215 pmcid: 5755138
Yau TO, Wu CW, Dong Y, Tang CM, Ng SSM, Chan FKL, Sung JJY, Yu J (2014) microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br J Cancer 111:1765–1771. https://doi.org/10.1038/bjc.2014.484
doi: 10.1038/bjc.2014.484 pubmed: 25233396 pmcid: 4453736
Ye X, Brabletz T, Kang Y, Longmore GD, Nieto MA, Stanger BZ, Yang J, Weinberg RA (2017) Upholding a role for EMT in breast cancer metastasis. Nat Cell Biol 547(7661):e1–e3. https://doi.org/10.1038/nature22816
doi: 10.1038/nature22816
Yin T, Wang C, Liu T, Zhao G, Zha Y, Yang M (2007) Expression of Snail in pancreatic cancer promotes metastasis and chemoresistance. J Surg Res 141(2):196–203. https://doi.org/10.1016/j.jss.2006.09.027
doi: 10.1016/j.jss.2006.09.027 pubmed: 17583745
Yu J, Ohuchida K, Mizumoto K, Sato N, Kayashima T, Fujita H, Nakata K, Tanaka M (2010) MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer 9:169
doi: 10.1186/1476-4598-9-169
Yu J et al (2012) MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res 18(4):981–992. https://doi.org/10.1158/1078-0432.CCR-11-2347
doi: 10.1158/1078-0432.CCR-11-2347 pubmed: 22114139
Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q, Chen C (2008) Profiling of 95 MicroRNAs in Pancreatic Cancer Cell Lines and Surgical Specimens by Real-Time PCR Analysis. World J Surg 33(4):698–709. https://doi.org/10.1007/s00268-008-9833-0
doi: 10.1007/s00268-008-9833-0
Zhang C, Kang C, You Y, Pu P, Yang W, Zhao P, Wang G, Zhang A, Jia Z, Han L, Jiang H (2009) Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. Int J Oncol 34(6):1653–1660. https://doi.org/10.3892/ijo_00000296
doi: 10.3892/ijo_00000296 pubmed: 19424584
Zhang C, Zhang J, Hao J, Shi Z, Wang Y, Han L, Yu S, You Y, Jiang T, Wang J, Liu M, Pu P, Kang C (2012) High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med 10:119. https://doi.org/10.1186/1479-5876-10-119
doi: 10.1186/1479-5876-10-119 pubmed: 22681957 pmcid: 3403924
Zheng Q, Peskoe SB, Ribas J, Rafiqi F, Kudrolli T, Meeker AK, de Marzo AM, Platz EA, Lupold SE (2014) Investigation of mir-21, mir-141, and mir-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prosta-tectomy. Prostate 74(16):1655–1662. https://doi.org/10.1002/pros.22883
doi: 10.1002/pros.22883 pubmed: 25252191 pmcid: 4205269
Zhou X et al (2016) A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer. Oncotarget 7(43):69616–69624. https://doi.org/10.18632/oncotarget.11903

Auteurs

Maria Mortoglou (M)

Cancer Research Group, School of Life Sciences, University of Westminster, London, W1W 6UW, UK.

Aleksandra Buha Djordjevic (A)

Department of Toxicology, University of Belgrade, 11000, Belgrade, Serbia.

Vladimir Djordjevic (V)

First Surgical Clinic, Clinical Center of Serbia, Belgrade, Serbia.

Hunter Collins (H)

College of Medicine and the Department of Pharmacology and Physiology, Oklahoma State University Center for Health Sciences, 1111 West 17th Street, Tulsa, OK, 74107-1898, USA.

Lauren York (L)

College of Medicine and the Department of Pharmacology and Physiology, Oklahoma State University Center for Health Sciences, 1111 West 17th Street, Tulsa, OK, 74107-1898, USA.

Katherine Mani (K)

College of Medicine and the Department of Pharmacology and Physiology, Oklahoma State University Center for Health Sciences, 1111 West 17th Street, Tulsa, OK, 74107-1898, USA.

Elizabeth Valle (E)

College of Medicine and the Department of Pharmacology and Physiology, Oklahoma State University Center for Health Sciences, 1111 West 17th Street, Tulsa, OK, 74107-1898, USA.

David Wallace (D)

College of Medicine and the Department of Pharmacology and Physiology, Oklahoma State University Center for Health Sciences, 1111 West 17th Street, Tulsa, OK, 74107-1898, USA.

Pinar Uysal-Onganer (P)

Cancer Research Group, School of Life Sciences, University of Westminster, London, W1W 6UW, UK. p.onganer@westminster.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH